2025
April
Treg depletion in brain tumors enhances antitumor responses
April 30, 2025
Glioblastoma and metastases in the brain are difficult to treat with immunotherapy, in part due to poor immune infiltration and a suppressive immune microenvironment, which can be marked by Tregs. Investigating ways of targeting Tregs, Galvez-Cancino et al. investigated using a non-interleukin-2 (IL-2) blocking (NIB) anti-CD25 antibodies (anti-CD25NIB) for Treg depletion in brain...
Prime time: secondary prolonged DC priming boosts high-affinity T cell responses
April 23, 2025
After initial priming through interaction with dendritic cells (DCs), CD8+ T cells disengage and migrate, but little is known about how cytokine signals are transmitted or received by these cells for differentiation during this migration. Jobin, Seetharama, et al. visualized the dynamics of antigen-specific CD8+ T cells, as well as CD4+ T helper...
Unraveling the role of soluble CTLA-4
April 16, 2025
CTLA-4 is a well established immune checkpoint with a key a role in limiting autoimmunity, but it exists in both membrane-bound (mCTLA-4) and soluble (sCTLA-4) forms, and the different sources, kinetics, and functions of sCTLA-4 in particular are not fully understood. In research recently published in Immunity, Osaki and Sakaguchi explored numerous aspects...
KEYSTONE SYMPOSIA: Cancer Immunotherapy: Clinical Lessons to New Modalities
April 9, 2025
The ACIR team attended the Keystone Symposia on Cancer Immunotherapy: Clinical Lessons to New Modalities held on March 16-19, 2025 in Banff, AB, Canada. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. (This Keystone Symposia conference is available for On Demand viewing...
Translation dysregulation in cancer produces targetable antigens
April 2, 2025
Dysregulation of translation and protein synthesis is often observed in cancer, but whether this results in the production of targetable antigens has not been fully explored. Investigating this possibility, Weller, Bartok, and McGinnis et al. used CRISPR-Cas9 to study the effects of tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) – a tRNA transferase that...
